ALMS
Alumis Inc. Common Stock NASDAQ Listed Feb 22, 2021$23.41
+1.56%
vs $23.05
Mkt Cap $19.9B
52w Low $2.80
75.8% of range
52w High $29.98
50d MA $22.98
200d MA $16.59
P/E (TTM)
-8.2x
EV/EBITDA
—
P/B
66.1x
Debt/Equity
0.1x
ROE
-80.8%
P/FCF
-53.8x
RSI (14)
57.90
ATR (14)
$1.54
Beta
-0.61
50d MA
$22.98
200d MA
$16.59
Avg Volume
1.1M
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. It develops ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis, systemic lupus erythematosus, and non-infectious uveitis; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. The company was incorporated in 2021 and is headquartered in South San Francisco, California.
280 East Grand Avenue · South San Francisco, CA 94080 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 14, 2026 | AMC | -0.79 | -0.74 | +6.3% | 24.63 | -8.4% | -7.1% | -7.5% | +1.8% | +2.4% | +0.6% | — |
| Mar 19, 2026 | AMC | -0.97 | -0.95 | +2.1% | 25.38 | -2.1% | -1.3% | -6.8% | -1.2% | +7.5% | +6.1% | — |
| Nov 13, 2025 | AMC | -0.92 | -1.06 | -15.2% | 5.28 | -10.0% | +4.5% | +1.1% | +14.9% | +2.5% | +5.3% | — |
| Aug 13, 2025 | AMC | -1.11 | -1.17 | -5.4% | 4.42 | -5.9% | -0.7% | +8.2% | +2.1% | -2.5% | -6.8% | — |
| May 14, 2025 | AMC | -1.47 | -1.82 | -23.8% | 4.51 | -0.4% | +18.6% | +5.0% | +5.9% | -18.0% | -2.0% | — |
| Mar 19, 2025 | AMC | -1.40 | -0.23 | +83.6% | 4.37 | -2.1% | -18.3% | +5.0% | +0.8% | +5.8% | +23.0% | — |
| Nov 13, 2024 | AMC | -1.64 | -1.73 | -5.5% | 10.81 | +1.0% | -13.0% | -6.0% | -2.4% | +19.8% | -6.9% | — |
| Aug 13, 2024 | AMC | -4.50 | -23.10 | -413.3% | 12.54 | -2.3% | +1.4% | +1.3% | -0.5% | +1.6% | +0.0% | — |
| Mar 31, 2024 | AMC | — | -0.96 | — | — | — | — | — | — | — | — | — |
| Dec 31, 2023 | AMC | — | -4.50 | — | — | — | — | — | — | — | — | — |
| Sep 30, 2023 | AMC | — | -1.13 | — | — | — | — | — | — | — | — | — |
| Jun 29, 2023 | AMC | — | -0.70 | — | — | — | — | — | — | — | — | — |
| Mar 31, 2023 | AMC | — | -0.69 | — | — | — | — | — | — | — | — | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 15 | H.C. Wainwright | Downgrade | Buy → Neutral | $25 | $24.63 | $22.55 | -8.4% | -7.1% | -7.5% | +1.8% | +2.4% | +0.6% |
| Mar 30 | Chardan Capital | Maintains | Buy → Buy | — | $24.80 | $24.00 | -3.2% | -18.5% | +9.0% | +3.2% | +2.8% | -6.1% |
| Mar 30 | Oppenheimer | Maintains | Outperform → Outperform | — | $24.80 | $24.00 | -3.2% | -18.5% | +9.0% | +3.2% | +2.8% | -6.1% |
| Mar 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $24.80 | $24.00 | -3.2% | -18.5% | +9.0% | +3.2% | +2.8% | -6.1% |
| Mar 20 | Chardan Capital | Maintains | Buy → Buy | — | $25.38 | $24.84 | -2.1% | -1.3% | -6.8% | -1.2% | +7.5% | +6.1% |
| Mar 20 | Morgan Stanley | Maintains | Overweight → Overweight | — | $25.38 | $24.84 | -2.1% | -1.3% | -6.8% | -1.2% | +7.5% | +6.1% |
| Jan 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $18.18 | $18.50 | +1.8% | +7.6% | +7.8% | +4.8% | +10.1% | -0.7% |
| Jan 7 | Guggenheim | Maintains | Buy → Buy | — | $16.23 | $17.39 | +7.1% | +10.4% | +1.5% | +7.6% | +7.8% | +4.8% |
| Jan 7 | Morgan Stanley | Maintains | Overweight → Overweight | — | $16.23 | $17.39 | +7.1% | +10.4% | +1.5% | +7.6% | +7.8% | +4.8% |
| Jan 7 | Leerink Partners | Maintains | Outperform → Outperform | — | $16.23 | $17.39 | +7.1% | +10.4% | +1.5% | +7.6% | +7.8% | +4.8% |
| Jan 6 | Wells Fargo | Maintains | Overweight → Overweight | — | $8.31 | $22.20 | +167.1% | +95.3% | +10.4% | +1.5% | +7.6% | +7.8% |
| Dec 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.58 | $10.59 | +0.1% | +4.5% | +2.1% | -1.0% | +2.4% | -0.4% |
| Aug 15 | Morgan Stanley | Maintains | Overweight → Overweight | — | $4.39 | $4.45 | +1.4% | +8.2% | +2.1% | -2.5% | -6.8% | +4.3% |
| Aug 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.42 | $4.16 | -5.9% | -0.7% | +8.2% | +2.1% | -2.5% | -6.8% |
| Jul 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.86 | $4.12 | +6.7% | +0.5% | +4.1% | -2.2% | +3.8% | +1.0% |
| May 15 | Oppenheimer | Maintains | Outperform → Outperform | — | $4.51 | $4.49 | -0.4% | +18.6% | +5.0% | +5.9% | -18.0% | -2.0% |
| Apr 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.33 | $4.23 | -2.3% | -4.4% | -7.5% | +19.8% | -4.1% | -1.1% |
| Apr 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.70 | $4.82 | +2.6% | +5.7% | -5.2% | -8.5% | -0.7% | -3.7% |
| Mar 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.00 | $3.82 | -4.5% | +23.0% | -4.5% | +20.0% | +8.9% | +17.9% |
| Mar 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.37 | $4.28 | -2.1% | -18.3% | +5.0% | +0.8% | +5.8% | +23.0% |
| Mar 20 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $4.37 | $4.28 | -2.1% | -18.3% | +5.0% | +0.8% | +5.8% | +23.0% |
| Mar 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.85 | $4.66 | -3.9% | -1.2% | +4.4% | -8.2% | -0.4% | -5.3% |
| Mar 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.88 | $4.70 | -3.7% | -0.6% | -1.2% | +4.4% | -8.2% | -0.4% |
| Mar 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.65 | $4.70 | +1.1% | -2.4% | +1.1% | +2.8% | +8.1% | -4.3% |
| Feb 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.59 | $5.33 | -19.1% | -14.0% | -15.0% | +3.9% | +0.4% | +1.4% |
| Jan 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.45 | $8.50 | +0.6% | +4.0% | -8.4% | -4.5% | -9.0% | +2.9% |
| Dec 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.63 | $8.51 | -1.4% | +2.2% | -5.1% | -3.9% | +4.6% | -4.2% |
| Nov 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.81 | $10.92 | +1.0% | -13.0% | -6.0% | -2.4% | +19.8% | -6.9% |
No insider trades available.
8-K · 2.02
!! High
Alumis Inc. -- 8-K 2.02: Earnings Results
Alumis Inc. reported earnings results with details available in the attached press release, providing investors with updated financial performance metrics for investment evaluation.
May 14
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
ALMS is adding standard forward-looking statement disclaimers to protect against litigation, suggesting management expects continued uncertainty or competitive pressures ahead.
Mar 30
8-K
Unknown — 8-K Filing
Alumis' Phase 3 validation of envudeucitinib for psoriasis represents a major de-risking event that could drive significant upside if FDA approval proceeds, making this a pivotal inflection point for the stock.
Mar 19
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Vanguard Capital Management Llc | 4,032,266 | $89M | New | Mar 2026 |
| 2 | Ubs Group Ag | 3,054,865 | $67M | Added | Mar 2026 |
| 3 | Foresite Capital Management V, Llc | 5,779,348 | $56M | — | Dec 2025 |
| 4 | Samsara Biocapital, Llc | 5,756,984 | $56M | Added | Dec 2025 |
| 5 | Mpm Bioimpact Llc | 2,386,529 | $53M | Reduced | Mar 2026 |
| 6 | Janus Henderson Group Plc | 2,124,408 | $47M | New | Mar 2026 |
| 7 | Invesco Ltd. | 1,511,537 | $33M | Added | Mar 2026 |
| 8 | Marshall Wace, Llp | 1,172,749 | $26M | Added | Mar 2026 |
| 9 | Fmr Llc | 973,782 | $21M | Added | Mar 2026 |
| 10 | Jpmorgan Chase & Co | 861,575 | $17M | Added | Mar 2026 |
| 11 | Yu Fan | 776,845 | $17M | New | Mar 2026 |
| 12 | Vanguard Portfolio Management Llc | 712,608 | $16M | New | Mar 2026 |
| 13 | Two Sigma Investments, Lp | 658,115 | $14M | Added | Mar 2026 |
| 14 | Millennium Management | 606,284 | $13M | Reduced | Mar 2026 |
| 15 | D.e. Shaw & Co | 572,129 | $13M | Added | Mar 2026 |
| 16 | Northern Trust Corp | 563,522 | $12M | Added | Mar 2026 |
| 17 | Prudential Financial Inc | 538,733 | $12M | New | Mar 2026 |
| 18 | Morgan Stanley | 1,013,058 | $10M | Added | Dec 2025 |
| 19 | Point72 Asset Management | 362,985 | $8M | New | Mar 2026 |
| 20 | Citadel Advisors Llc | 351,507 | $8M | Added | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$19.91B
Enterprise Value
$19.60B
P/E (TTM)
-8.19x
Forward P/E
—
PEG Ratio
0.47x
P/B
66.07x
P/S
827.67x
P/FCF
-53.77x
EV/EBITDA
—
Shares Out
850.3M
Financials (TTM)
Revenue
$24.1M
Net Income
-$243.3M
EBITDA
-$423.7M
Free Cash Flow
-$370.2M
Op Cash Flow
-$369.5M
EPS Basic
$-2.86
EPS Diluted
$-2.86
EPS Forward
$-2.94
Gross Margin
85.5%
Op Margin
-1776.3%
Net Margin
-1011.8%
Balance Sheet
Total Assets
$411.9M
Total Liab.
$110.6M
Total Equity
$301.3M
Cash
$308.5M
LT Debt
$0
Book Value/Sh
$0.35
Debt/Equity
0.12x
Current Ratio
4.34
Quick Ratio
4.34
Returns & Growth
ROE
-80.8%
ROA
-59.1%
ROIC
-120.2%
Rev Growth YoY
+0.0%
EPS Growth YoY
+72.5%
Price Returns
2W
-12.3%
1M
-12.5%
3M
-27.2%
6M
+181.6%
12M
+517.1%
Technicals
52W High
$29.98
52W Low
$2.80
50d MA
$22.98
200d MA
$16.59
RSI (14)
57.90
ATR (14)
$1.54
Beta
-0.61
Avg Volume
1.1M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$38.44
High
$50.00
Low
$32.00
Median
$37.00
Data updated apr 24, 2026 5:25pm
· Source: financialmodelingprep.com